select trial semaglutide nejm Trial: 2.4 mg Cuts Cardiovascular Risk in Obesity (NEJM 2023) Semaglutide and Cardiovascular Outcomes in

The reactions are shown here, with R and R representing the two gluten molecules and with cysteine as the reducing agent: RSSR + cysSH RSScys + RSH RSScys + cysSH cysSScys + RSH These reactions reduce the number of cross-links between the gluten subunits proportional to the number of cysteine or glutathione molecules added and are reversible so that the degree of relaxation can be controlled

This is not just a pharmaceutical issue

Gross hematuria is less common but more likely to indicate an underlying condition that needs evaluation

Understanding vascular ultrasound results needs a healthcare providers help

In the SURPASS-2 head-to-head trial (Fras et al., NEJM 2021), tirzepatide 15mg reduced body weight 5.5kg more than semaglutide 1mg over 40 weeks in a type 2 diabetes population